|
WO2021062246A1
|
|
Crf receptor antagonists and methods of use
|
|
WO2021050977A1
|
|
Processes for the synthesis of valbenazine
|
|
US2021052558A1
|
|
Methods for the administration of certain VMAT2 inhibitors
|
|
WO2020227672A1
|
|
Methods for the administration of certain vmat2 inhibitors
|
|
US2020268744A1
|
|
Methods for the Administration of Certain VMAT2 Inhibitors
|
|
TW202033193A
|
|
Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
|
|
TW202033521A
|
|
Processes for preparing a vmat2 inhibitor
|
|
CA3112994A1
|
|
Methods for the administration of comt inhibitors
|
|
WO2020072886A1
|
|
Methods for the administration of comt inhibitors
|
|
SG11202100303QA
|
|
Methods for the administration of certain vmat2 inhibitors
|
|
BR112020024018A2
|
|
vmat2 inhibitor compounds, compositions and methods related to them
|
|
EP3684333A2
|
|
High dosage valbenazine formulation and compositions, methods, and kits related thereto
|
|
WO2018200605A1
|
|
Use of valbenazine for treating levodopa-induced dyskinesia
|
|
WO2018195121A1
|
|
Vmat2 inhibitor compounds and compositions thereof
|
|
JOP20180035A1
|
|
Valbenazine salts and polymorphs thereof
|
|
WO2018164996A1
|
|
Dosing regimen for valbenazine
|
|
WO2018102673A1
|
|
Use of valbenazine for treating schizophrenia or schizoaffective disorder
|
|
AU2017435893A1
|
|
Methods for the administration of certain VMAT2 inhibitors
|
|
AU2017395704A1
|
|
Methods for the administration of certain VMAT2 inhibitors
|
|
CN108925135A
|
|
Prepare (S)-(2R, 3R, 11bR) -3- isobutyl group -9,10- dimethoxy -2,3,4,6,7,11b- hexahydro -1H- pyrido [2,1-a] isoquinolin-2-yl 2- amino -3 Methylbutanoic acid ester two (4- toluenesulfonate) synthetic method
|
